Single-dose of adrecizumab versus placebo in acute cardiogenic shock (ACCOST-HH): an investigator-initiated, randomised, double-blinded, placebo-controlled, multicentre trial

Autor: Karakas, Mahir *, Akin, Ibrahim, Burdelski, Christoph, Clemmensen, Peter, Grahn, Hanno, Jarczak, Dominik, Keßler, Mirjam, Kirchhof, Paulus, Landmesser, Ulf, Lezius, Susanne, Lindner, Diana, Mebazaa, Alexandre, Nierhaus, Axel, Ocak, Anil, Rottbauer, Wolfgang, Sinning, Christoph, Skurk, Carsten, Söffker, Gerold, Westermann, Dirk, Zapf, Antonia, Zengin, Elvin, Zeller, Tanja, Kluge, Stefan
Zdroj: In The Lancet Respiratory Medicine March 2022 10(3):247-254
Databáze: ScienceDirect